-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $46

Benzinga·04/29/2025 10:28:12
Listen to the news
Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $45 to $46.